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Edited by Veli-Pekka LehtoAbstract The contributions of membrane type-1 matrix
metalloproteinase (MT1-MMP) and of the glucose-6-phosphate
transporter (G6PT) in sphingosine-1-phosphate (S1P)-mediated
Ca2+ mobilization were assessed in glioblastoma cells. We show
that gene silencing of MT1-MMP or G6PT decreased the extent
of S1P-induced Ca2+ mobilization, chemotaxis, and extracellu-
lar signal-related kinase phosphorylation. Chlorogenic acid and
()-epigallocatechin-3-gallate, two diet-derived inhibitors of
G6PT and of MT1-MMP, respectively, reduced S1P-mediated
Ca2+ mobilization. An intact MT1-MMP/G6PT signaling axis
is thus required for eﬃcient Ca2+ mobilization in response to bio-
active lipids such as S1P. Targeted inhibition of either MT1-
MMP or G6PT may lead to reduced inﬁltrative and invasive
properties of brain tumor cells.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Glioblastoma multiform is the most commonly occurring
primary brain tumor in adults and is highly malignant, dis-
playing increased vascularization, aggressive growth and
invasion into surrounding brain tissue [1]. Among the serum-
derived lipid and growth factors that exhibit chemotactic inﬂu-
ences towards glioblastoma cells, sphingosine-1-phosphate
(S1P) is a bioactive lipid that stimulates growth and invasive-
ness of glioblastoma cell and that signals through a family of
ﬁve G-protein-coupled receptors termed S1PR(1-5) [2]. The
S1P receptor (S1PR) contribution to intracellular calcium
(Ca2+) homeostasis and stimulation of glioblastoma cell prolif-Abbreviations: CHL, chlorogenic acid; ECM, extracellular matrix;
EGCg, ()-epigallocatechin-3-gallate; ER, endoplasmic reticulum;
ERK, extracellular signal-related kinase 1/2; bFGF, basic ﬁbroblast
growth factor; G6PT, glucose-6-phosphate transporter; MMP, matrix
metalloproteinase; MT1-MMP, membrane type-1 MMP; S1P, sphin-
gosine-1-phosphate; S1PR, S1P receptor; SphK, sphingosine kinase
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lated protein kinase (ERK) MAP kinase [3,4]. Among the
two sphingosine kinase (SphK) isoforms, SphK-1 correlates
with short survival of glioblastoma patients [5,6], and is
overexpressed in brain tumor-derived endothelial cells [7].
Consequently, the generation of S1P is hypothesized to con-
tribute to the acquisition and the maintenance of the multidrug
resistance phenotype in brain tumors as well as to exert chemo-
tactic migration eﬀects in numerous types of cells including
ovarian cancer cells [8], HT-1080 ﬁbrosarcoma cells [9], U-87
glioblastoma cells [10] and mesenchymal stromal cells [11].
The molecular players that link the control of S1P-mediated
intracellular Ca2+ mobilization to cell migration and to extra-
cellular matrix (ECM) degradation remain to be investigated.
Recent evidence from our laboratory identiﬁed a crucial
signaling axis composed of a cell surface membrane-bound
matrix metalloproteinase (MT1-MMP) and of an endoplasmic
reticulum (ER)-embedded glucose-6-phosphate transporter
(G6PT) which functions as a bioswitch in the regulation of
glioblastoma cell survival and migration [12]. Interestingly, ge-
netic deﬁciencies in G6PT cause a clinical condition where pa-
tients have impaired neutrophil chemotaxis and Ca2+ ﬂux [13].
These ﬁndings, along with G6PTs endoplasmic/sarcoplasmic
reticulum Ca2+ sequestration function [14], demonstrate that
G6PT is not just a G6P transport protein but may also poten-
tially contribute to intracellular Ca2+ homeostasis. This
explains, in part, why chlorogenic acid (CHL), among the
most potent functional inhibitor of G6PT [15], inhibited
S1P-induced glioblastoma cell migration as well as the rapid,
S1P-induced ERK phosphorylation in glioblastoma cells [16].
In this study, we speciﬁcally assessed whether gene silencing
of MT1-MMP or G6PT may aﬀect S1P-mediated intracellular
Ca2+ mobilization and glioblastoma cell migration in response
to S1P. We report that an intact, functional MT1-MMP/G6PT
signaling axis is required for eﬃcient Ca2+ mobilization in
response to circulating bioactive lipids such as S1P, suggesting
that targeted inhibition of either MT1-MMP or G6PT func-
tion may lead to reduced inﬁltrative and invasive properties
of brain tumor cells.2. Materials and methods
2.1. Materials
Sodium dodecylsulfate (SDS), bovine serum albumin (BSA),
PD98059, U73122, Y27632, sphingosine-1-phosphate (S1P), thapsigar-
gin and verapamil were purchased from Sigma (Oakville, ON). TRIzolblished by Elsevier B.V. All rights reserved.
800 S. Fortier et al. / FEBS Letters 582 (2008) 799–804reagent for total RNA extraction was from Life Technologies. The
anti-phospho-ERK antibody was from Cell Signaling Technology
(Beverly, MA) while the polyclonal anti-ERK antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA), and used for immuno-
blotting procedures as described previously [16].
2.2. Transfection method and RNA interference
The U-87 glioblastoma cells were transiently transfected with the
cDNA constructs encoding either MT1-MMP [17] or G6PT [18], or
with 20 nM siRNA (see below) using Lipofectamine 2000 (Invitrogen).
The occurrence of MT1-MMP or G6PT speciﬁc gene knockdown was
evaluated by semi-quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) with the One-Step RT-PCR Kit (Invitrogen) and
validated by assessing MT1-MMP-mediated proMMP-2 activation
with concanavalin-A using gelatin zymography of the conditioned
media [11]. Mock transfections of U-87 cultures with pcDNA (3.1+)
were used as controls. Small interfering RNAs against MT1-MMP
(siMT1-MMP) and G6PT (siG6PT), and mismatch siRNA were syn-
thesized by EZBiolab Inc. (Westﬁeld) and annealed to form duplexes.
The sequence of the siMT1-MMP and siG6PT used in this study are as
follows: siMT1-MMP: 5 0-CCAGAAGCUGAAGGUAGAAdTdT-3 0
(sense) and 5 0-UUCUACCUUCAGCUUCUGGdTdT-3 0 (antisense);
siG6PT: 5 0-CGAAACAUCCGCACCAAGAdTdT-3 0 (sense) and
5 0-UCUUGGUGCGGAUGUUUCGdTdT-3 0 (antisense) [12,16].
2.3. Calcium mobilization assay
U-87 glioblastoma cells were cultured in 4-well Labtek chambers
(Nalge Nunc). Culture media was then changed to HEPES-buﬀered sal-
ine solution (HBSS) (mM: 121 NaCl, 5.4 KCl, 0.8 Mg2SO4, 25 HEPES,
1.8 CaCl2 and 6.0 NaHCO3 at pH 7.3) and loaded with 2 lM Fluo-3
AM (Molecular Probes) with an equivalent volume of 20% Pluronic
F127 and 5 lM Verapamil for 45 min at 37 C in the dark. Thereafter,
cells were washed with HBSS and the loaded dye was allowed to deeste-
rify for 45 min at room temperature in the dark. Following transfer to a
Ca2+-free solution (HBSS without CaCl2), additions were made in an
open chamber conﬁguration at room temperature. The cells were exam-
ined with a laser scanning confocal (Bio-Rad) Nikon TE300microscope
with an Apochromatic 40X N.A. 1.0 objective lens. Fluorescence was
excited by an argon laser at 488 nm and emission was collected with a
515 nm ﬁlter. Data were analyzed with Laser Sharp 2.1 T, Time Course
1.0 software. The individual ﬂuorescence intensities of 20–30 cells per
ﬁeld were used to obtain a mean ﬂuorescence for each experiment.Fig. 1. Pharmacological inhibition of sphingosine-1-phosphate-induced ca
phosphate (S1P) were used to treat serum-starved U-87 glioblastoma cells for
PAGE and immunoblotting was performed to detect the extent of ERK ph
phosphorylation, and data are represented by a ratio of P-ERK/ERK from
Ca2+ mobilization were induced with 1 lM S1P as described in Section 2. Cel
CHL, PD98059, U73122, or Y27632 for 30 min prior to stimulation with S1P.
shown.2.4. Analysis of U-87 glioblastoma cell migration
U-87 cell migration was assessed using modiﬁed Boyden chambers.
The upper surfaces of Transwell inserts (8 lm pore size; Costar, Acton,
MA) were pre-coated with 0.2% gelatin. The Transwells were then
assembled in a 24-well plate and the lower chamber was ﬁlled with
serum-free MEM or MEM supplemented with either 1 lM S1P or
20 ng/ml basic ﬁbroblast growth factor (bFGF). Cells were collected
by trypsinization, washed and resuspended in serum-free medium;
105 cells were then inoculated onto the upper side of each modiﬁed
Boyden chamber. The plates were placed at 37 C in 5% CO2/95%
air, and migration left to proceed for 6 h. Cells that had migrated to
the lower surfaces of the ﬁlters were ﬁxed with 10% formalin phosphate
and stained with 0.1% crystal violet-20% methanol (v/v). Images of at
least ﬁve random ﬁelds per ﬁlter were digitized (100· magniﬁcation).
The average number of migrating cells per ﬁeld was quantiﬁed using
Northern Eclipse software (Empix Imaging Inc.). Migration data are
expressed as a mean value derived from at least four independent
experiments.3. Results
3.1. Pharmacological inhibition of sphingosine-1-phosphate-
induced calcium mobilization
ERK phosphorylation represents, among the early intracel-
lular Ca2+-dependent events, an eﬃcient means by which to
examine sphingosine-1-phosphate (S1P) eﬀects. U-87 glioblas-
toma cells were thus exposed for 2 min to various doses of S1P
(Fig. 1A) and the extent of ERK phosphorylation found
optimal at 1 lM S1P (Fig. 1B). That S1P concentration was
then used throughout the remaining study, and the contri-
bution of the S1P G-protein-coupled receptors (S1PRs)
intracellular signaling pathways involving the phospholipase
C, MAPK and RhoA/ROK assessed [19]. While Ca2+ mobili-
zation upon S1P treatment was rapidly and transiently induced
in the control condition, that mobilization was inhibited in
PD98059 (a MEK kinase inhibitor), Y27632 (a RhoA/ROK
inhibitor), and in U73122 (a phospholipase C antagonist)lcium mobilization. (A) Increasing concentrations of sphingosine-1-
2 min. Following treatment, 20 lg of cell lysates were loaded on SDS–
osphorylation. (B) Scanning densitometry was used to quantify ERK
one representative experiment. (C) U-87 glioblastoma cell cultures and
ls were pre-treated with either vehicle (Control) or 10 lM EGCg, EGC,
A representative Ca2+ mobilization proﬁle, out of three experiments, is
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naling cascades for S1P were required to elicit proper Ca2+
mobilization in part through a receptor-dependent mechanism
acting via G(i)/ERK pathway in conjunction with activation of
Rho- and phospholipase C-mediated signals. When cells were
treated with either epigallocatechin-3-gallate (EGCg) or chlor-
ogenic acid (CHL), two diet-derived molecules shown to inhi-
bit, respectively MT1-MMP or microsomal G6P transport
functions [20–22], we also observed a decrease in S1P-induced
Ca2+ mobilization (Fig. 1C). Interestingly, epigallocatechin
(EGC) failed to inhibit S1P-induced Ca2+ mobilization sug-
gesting a structure–function relationship of the gallate moiety
previously shown to target the cooperative functions of MT1-
MMP [23]. Following each of the above tested inhibitors, Ca2+
release from ER was induced as a control by the addition of
5 lM Thapsigargin (not shown).
3.2. Gene silencing of MT1-MMP and of G6PT impairs
sphingosine-1-phosphate-mediated calcium mobilization
The relevance of each MT1-MMP and G6PT was assessed
with respect to Ca2+ mobilization by S1P. Gene silencing strat-
egies using speciﬁc siRNA was used as previously described
[18,24] and eﬃciency of gene silencing conﬁrmed by
RT-PCR (Fig. 2A). MT1-MMP function was eﬃciently
reduced by gene silencing since concanavalin-A, a known
MT1-MMP inducer and proMMP-2 activator [25], was unable
to trigger proMMP-2 activation (Fig. 2B, siMT1-MMP). In
contrast, cells that overexpressed recombinant MT1-MMP
were found to activate proMMP-2 into MMP-2 and this eﬀect
was ampliﬁed by concanavalin-A treatment (Fig. 2B). Gene
silencing of G6PT did not aﬀect concanavalin-As ability to in-
duce proMMP-2 activation. However, transient G6PT cDNA
cell transfections lead to decreased proMMP-2 activation by
concanavalin-A (Fig. 2B) in agreement with the prosurvival
role played by G6PT [12]. When S1P-induced Ca2+ mobiliza-Fig. 2. Gene silencing of MT1-MMP and of G6PT impairs sphingosine-1-p
from mock-, siMT1-MMP-, and siG6PT-transfected U-87 cells. The eﬃcienc
were visualized on agarose gels stained with ethidium bromide. (B) Seru
transfected U-87 cells were treated in the presence or absence of 10 lM concan
proMMP-2 activation was assessed by gelatin zymography as described in Se
assessed for Ca2+ mobilization induced with 1 lM sphingosine-1-phosphate
proﬁle, out of three experiments, is shown.tion was assessed, both siMT1-MMP- and siG6PT-transiantly
transfected cells showed a signiﬁcant decrease in Ca2+ mobili-
zation (Fig. 2C). On the other hand, cells that overexpressed
MT1-MMP demonstrated an increase in Ca2+ mobilization
by S1P, while those that overexpressed G6PT did not exhibit
any changes when compared to mock-transfected cells
(Fig. 2C). SiMT1-MMP and siG6PT did not block thapsigar-
gin-induced Ca2+ release (not shown). Collectively, this
conﬁrms the primary cooperative role of MT1-MMP with
S1P, while G6PT, because of its inability to increase S1P-med-
iated Ca2+ mobilization in G6PT-transfected cells, may only
play a complementary role in the MT1-MMP/G6PT signaling
axis.
3.3. Gene silencing of both G6PT and MT1-MMP suppresses
ERK phosphorylation by S1P
We assessed the impact of MT1-MMP and G6PT in S1P-in-
duced ERK phosphorylation. Cells were transiently transfected
with siRNA speciﬁc for MT1-MMP and G6PT as described in
Section 2. Cells were then incubated in the presence of S1P for
up to 20 min and the extent of ERK phosphorylation was
assessed by Western blotting (Fig. 3A). In agreement with the
Ca2+ mobilization eﬀects, we found that S1P triggered a rapid
but transient phosphorylation of ERK, while silencing of both
MT1-MMP and G6PT genes almost completely abolished
ERK phosphorylation (Fig. 3B).
3.4. Gene silencing of both G6PT and MT1-MMP suppresses
S1P chemotactic eﬀects
S1P is among the most potent chemotactic agents and has
been found to induce cell migration in multiple cell models
[26]. Given that Ca2+ mobilization, as well as ERK phosphor-
ylation, in response to S1P may in part play a role in U-87 cell
migration, we assessed the impact of MT1-MMP and G6PT in
cell migration. Cells were transiently transfected with siRNAhosphate-mediated calcium mobilization. (A) Total RNA was isolated
y of gene silencing was assessed using RT-PCR, and cDNA amplicons
m-starved mock-, siMT1-MMP-, MT1-MMP, siG6PT, and G6PT-
avalin-A for 18 h. Conditioned media were harvested and the extent of
ction 2. (C) The above transfected U-87 glioblastoma cell cultures were
(S1P) as described in Section 2. A representative Ca2+ mobilization
Fig. 4. Gene silencing of both G6PT and MT1-MMP abrogates
sphingosine-1-phosphate chemotactic eﬀects. (A) U-87 glioblastoma
cells were transiently transfected with siRNA speciﬁc for MT1-MMP
and G6PT as described in Section 2. Cells were then assessed for
migration using modiﬁed Boyden chambers in the absence (white bars)
or the presence of 1 lM sphingosine-1-phosphate (S1P, black bars), or
20 ng/ml bFGF (grey bars). Cell migration proceeded for 6 h and was
quantiﬁed (B). Values shown represent the means ± S.D. of a
representative experiment where 5 random ﬁelds per ﬁlter were
Fig. 3. Gene silencing of both G6PT and MT1-MMP abrogates ERK
phosphorylation by sphingosine-1-phosphate. (A) U-87 glioblastoma
cells were transiently transfected with siRNA speciﬁc for MT1-MMP
and G6PT as described in Section 2. Cells were then incubated in the
presence of sphingosine-1-phosphate (S1P) for up to 20 min and the
expression of phosphorylated ERK (P-ERK) and of total ERK was
assessed in cell lysates by Western blotting. (B) Quantiﬁcation was
performed using scanning densitometry, and results are expressed as
the ratio of P-ERK/total ERK for each of the conditions. A
representative Western blot, out of three experiments, is shown.
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using modiﬁed Boyden chambers (Fig. 4A). While basal cell
migration (Fig. 4B, white bars) remained relatively unaﬀected,
silencing of both the MT1-MMP and G6PT genes resulted in
an overall 55–80% decrease in cell migration in response to
S1P (Fig. 4B, black bars). Interestingly, gene silencing of
MT1-MMP and of G6PT did not aﬀect U-87 cell migration
in response to bFGF (Fig. 4B, grey bars), suggesting that the
MT1-MMP/G6PT signaling axis is speciﬁcally involved in
the S1P-induced chemotaxis but not in non-lipid bFGF-medi-
ated signaling.
counted for each condition. Probability values of less than 0.05 using
Students unpaired t-test were considered signiﬁcant when S1P- or
bFGF-induced cell migration was compared to mock-transfected cells,
and an asterisk (*) identiﬁes such signiﬁcance.4. Discussion
The ER is primarily known as the site of synthesis and
folding of secreted, membrane-bound, and some organelle-
targeted proteins. It is also a multifunctional metabolic
compartment that controls entry and release of Ca2+, sterol
biosynthesis, apoptosis and the release of arachidonic acid
[27]. As such, metabolic proﬁling of cell growth and death in
cancer is already used in order to identify the changes in
glucose utilization for macromolecule synthesis in cancer
[28]. Release of Ca2+ from ER stores was observed upon S1P
activation [29, this study] and was correlated with the activa-
tion of the small GTPase Rac [29]. Interestingly, the coordi-
nate modulation of MMP-2 activity and of MT1-MMP
expression/processing by Rac1 is consistent with MT1-MMPs
role in cell invasion [30]. Among the several brain tumor-de-
rived cell lines tested, G6PT expression was found to be the
highest in U-87 glioblastoma cells [16]. This suggests that met-
abolic adaptative capacity, in part through G6PT, may regu-
late the invasive phenotype of aggressive cancer cells. Given
the ER localization of G6PT and the crucial role that the
ER fulﬁlls as a metabolic compartment, intracellular regula-tion of Ca2+ ﬂux, cytosolic ATP and G6P levels would be
among the parameters that G6PT could modulate in the trans-
formed proliferating cells. We thus propose that G6PT further
acts as a mediator in the regulation of cancer cell survival and
ECM degradation signaling. In fact, evidence that regulation
of G6PT expression may function as a bioswitch enabling cells
to promote either migration or cell death processes through
MT1-MMP cytoplasmic domain signaling was recently pro-
vided [24].
Recent evidence has revealed a molecular link between
MT1-MMP and S1P signaling in mesenchymal stromal cell
and endothelial cell migration, survival, ECM proteolysis,
and cytoskeletal rearrangement [19,24,31,32]. We now high-
light a signiﬁcant and new contribution of the MT1-MMP/
G6PT signaling axis that may further regulate S1P activity
as a second messenger in mobilizing intracellular Ca2+ in tu-
mor cells. Several explanations for this MT1-MMP/S1P coop-
erative eﬀect have been forwarded. Among these, RhoA
signaling, a crucial intermediate step in S1P transduction was
S. Fortier et al. / FEBS Letters 582 (2008) 799–804 803increased in MT1-MMP-transfected cells [21]. More recently,
S1P was shown to regulate endothelial cell locomotion by
inducing the association of MT1-MMP with the adaptor pro-
tein p130Cas at the leading edge of migrating cells [33].
Although the ability of S1P to increase cytosolic Ca2+ has been
characterized in terms of the individual S1PRs involved [4],
speciﬁc studies to identify the S1PR that cooperates with
MT1-MMP activity may however be challenging. Ca2+ mobi-
lization being a hallmark of most S1PRs [34], it can be antici-
pated that one S1PR would take the functional relay upon
another. Design and use of speciﬁc siRNA targeting each of
the S1PRs (S1P-1 to -5) should shed light on how MT1-
MMP cooperates with S1PRs functions in the control of cell
migration, cell survival, and ECM degradation. It is known
that S1P1 and S1P2 receptors are expressed on glioblastoma
cells [35], and that S1P2 is likely responsible for the eﬀect of
PLC, Ca2+ release and PLD [10].
Altered expression, maturation and traﬃcking of MT1-
MMP to the plasma membrane were observed in diabetic
states [36,37], a condition known to upregulate the expres-
sion of G6PT [38]. G6PT expression was shown to be down-
regulated by MT1-MMP in mesenchymal stromal cells [24].
This is in agreement with the fact that cytoskeleton disorga-
nization, an early step in the activation process of matrix
metalloproteinase 2 (MMP-2) by MT1-MMP, is also associ-
ated with ER dysfunction and subsequent cell death. Fur-
thermore, recent studies suggest that the microtubule
cytoskeleton and the centrosomes (the microtubule cytoskel-
eton-organizing centers) are essential for the traﬃcking and
the internalization of the membrane-bound matrix metallo-
proteinase MT1-MMP [39], involved in brain tumor cell
invasion, ECM degradation and cell-ECM interaction [40].
Our results suggest that an intact, functional MT1-MMP/
G6PT signaling axis is required for eﬃcient Ca2+ mobiliza-
tion processes to take place in response to circulating bioac-
tive lipids such as S1P. Given that such axis regulates cell
survival and chemotaxis, targeted inhibition of either MT1-
MMP or G6PT function may lead to reduced inﬁltrative
and invasive properties of brain tumor cells. Documenting
the Ca2+-mediated roles and potential contribution of
G6PT in cancer cells will further help optimize or design
new anti-tumor therapies.
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